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Condensation, Implications and Contributions: 
• Assessment of prognostic ability of maternal characteristics, first trimester 
ultrasound and biomarkers to predict complications in monochorionic twin 
pregnancies 
• No prognostic test is currently available to predict which monochorionic twin 
pregnancies will develop twin-twin transfusion syndrome, intrauterine growth 
restriction, intrauterine fetal death. Although a significant association was found 
between nuchal translucency >95th centile in one/both fetuses and twin-twin 
transfusion syndrome, and crown-rump length discordance ≥10% and twin-twin 
transfusion syndrome, both demonstrated poor individual prognostic ability. We 
have revealed a lack of research investigating first trimester biomarkers in MC 
twin pregnancies. Different assessment methods and definitions of each variable 
and outcome were an issue and this highlights the need for a large cohort study 
to evaluate these factors. 
 
Short version of title: Early prognostic factors in monochorionic twin pregnancy 
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Abstract 
Objective: Assess ability of first trimester pregnancy related factors (ultrasound 
measurements, maternal characteristics, biomarkers) to predict complications in 
monochorionic twin pregnancies 
Data sources: MEDLINE, EMBASE, ISI Web of Science, CINAHL, the Cochrane 
Central Registration of Controlled Trials and Research Registers, and Google 
Scholar, from inception to 12 May 2017. Grey literature and bibliographies of articles 
were checked. 
Study eligibility criteria: Studies that reported ultrasound measurements, maternal 
characteristics, or potential biomarkers, measured in the first trimester in 
monochorionic diamniotic twin pregnancies, where the potential prognostic ability 
between the variable and twin-twin transfusion syndrome, growth restriction, or 
intrauterine fetal death could be assessed. 
Study appraisal and synthesis methods: Quality assessment was evaluated using 
the STROBE checklist by 2 reviewers independently. For meta-analysis, odds ratios 
using a random effects model, or standardized mean difference were calculated. If a 
moderate association was found, the prognostic ability was evaluated by calculating 
the sensitivity and specificity. Risk of heterogeneity was reported as I2 and 
publication bias was visually assessed by funnel plots and quantitatively by Egger’s 
test. 
Results: Forty-eight studies were eligible for inclusion. Twenty meta-analyses could 
be performed. A moderate association was demonstrated in 3 meta-analyses, 
between: NT>95th centile in one/both fetuses and TTTS (OR 2.29 [95%CI 1.05, 
4.96] I2=6.6%, 4 studies, 615 pregnancies); CRL discordance ≥10% and TTTS (OR 
2.43 [95%CI 1.13, 5.21] I2=14.1%, 3 studies, 708 pregnancies); and maternal 
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ethnicity and TTTS (OR 2.12 [95%CI 1.17, 3.83] I2=0.0%, 5 studies, 467 
pregnancies), but none demonstrated a prognostic ability for any outcome under 
investigation. 
Conclusions: It is not currently possible to predict adverse outcomes in 
monochorionic twin pregnancies. We have revealed a lack of research investigating 
first trimester biomarkers in monochorionic twin pregnancies. Different assessment 
methods and definitions of each variable and outcome were an issue and this 
highlights the need for a large cohort study to evaluate these factors. 
 
 
Keywords: biomarker, crown-rump length, first trimester, growth restriction, maternal 
characteristics, monochorionic, nuchal translucency, predict, prognostic factor, twin 
pregnancy, twin-twin transfusion syndrome, ultrasound 
 
Introduction 
Monochorionic (MC) twin pregnancies are considered high-risk because of the 
potential to develop the morbid conditions of twin-twin transfusion syndrome (TTTS), 
twin anemia polycythemia sequence (TAPS), or twin oligohydramnios-
polyhydramnios sequence (TOPS) (1, 2). Additionally, MC twins have a greater 
likelihood of developing selective intrauterine growth restriction (sIUGR), and single 
and double intrauterine fetal death (sIUFD and dIUFD) compared to dichorionic (DC) 
twins (3). Consequently, international professional guidelines advise that all MC twin 
pregnancies undergo ultrasound assessment of fetal growth, amniotic fluid volume, 
and umbilical artery Doppler velocimetry every 2 weeks from 16 weeks gestation (4-
6). However, the majority of MC twins will not develop any of these complications (7). 
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At present, no screening test is available to predict which MC twin pregnancy will 
develop complications and therefore all MC twins undergo the intensive antenatal 
surveillance that has an impact on patients and healthcare resources. 
 
Objectives 
To assess the ability of first trimester pregnancy related factors (ultrasound 
measurements, maternal characteristics, biomarkers) to predict complications in MC 
twin pregnancies.  
 
Methods 
This systematic review was performed according to a protocol designed a priori and 
registered on PROSPERO 
(www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015024975). It is 
reported according to the PRISMA guidelines (8). 
  
Eligibility criteria 
Studies that reported ultrasound measurements, maternal characteristics, or 
potential biomarkers, measured in the first trimester (i.e. up to 14 weeks gestation), 
in monochorionic diamniotic (MCDA) twin pregnancies that provided sufficient 
information to assess the association between the variable and outcome were 
eligible for inclusion. Monochorionicity had to have been confirmed either by the 
presence of the ‘T’ sign or absence of the ‘λ’ or ‘twin peak’ sign on first trimester 
ultrasound (9), or postnatally by placental examination. Studies with <5 MCDA twin 
pregnancies were excluded, as were those pregnancies affected by: major structural 
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or chromosomal anomalies, twin-reversed arterial perfusion (TRAP), miscarriage, 
sIUFD <14 weeks gestation, higher order multiple or monoamniotic pregnancies.  
 
Potential prognostic factors 
All first trimester potential prognostic factors were included. Data were extracted 
using the same cut-offs as reported by the authors. For meta-analysis thresholds 
were not combined (i.e. crown-rump length (CRL) discordance >10% was not 
combined with CRL discordance >20%). Maternal age and BMI were analyzed as 
continuous variables. Maternal ethnicity was dichotomized to ‘Caucasian’ and ‘non-
Caucasian’ to enable meta-analysis, parity was dichotomized to ‘multiparous’ and 
‘nulliparous’, maternal smoking was dichotomized to current ‘smoker’ and ‘non-
smoker’ with ex-smokers included in the ‘non-smoker’ group, and mode of 
conception was dichotomized to ‘spontaneous’ or ‘assisted reproductive technology 
(ART)’.  
 
Outcomes 
The outcomes evaluated were:  
• TTTS, irrespective of whether treatment was required/performed, and 
according to definitions used by authors of individual studies (see 
Supplementary File Table 1) including significant discrepancy in inter-twin 
amniotic fluid volumes as per Quintero (10). 
• Antenatal growth restriction only (AGR), based on estimated fetal weight 
(EFW) (irrespective of the presence of umbilical artery Doppler abnormalities), 
as defined by each study. Regardless of definition used within individual 
studies, we adopted the consensus definition of ≥20% inter-twin EFW 
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discordance as per the American College of Obstetricians and Gynecologists 
(ACOG), the International Society of Ultrasound in Obstetrics & Gynecology 
(ISUOG) and the Royal College of Obstetricians and Gynaecologists in the 
UK (RCOG) (4-6). 
• Postnatal growth restriction only (PGR), based on birthweight (BW) as defined 
by each study, but if reported as inter-twin discordance, must be ≥20% 
• Antenatal and postnatal growth restriction within the same pregnancy  
• Antenatal or postnatal growth restriction (AoPGR) which includes all the 
growth restricted pregnancies in the other three growth restriction groups 
(AGR, PGR, antenatal and growth restriction within the same pregnancy) 
• sIUFD after 14 weeks gestation 
• dIUFD after 14 weeks gestation 
Within our protocol the definitions of the outcomes were not pre-specified to allow for 
variation of definitions. Where a definition exists e.g. Quintero for TTTS, ≥20% for 
antenatal growth discordance, this was adopted for decisions regarding inclusion of 
studies for meta-analysis. For those analyses where there was variation in 
definitions, sensitivity analysis was employed where possible to determine the 
effects of the definition on the results.  
 
Information sources 
Electronic databases were searched: MEDLINE, EMBASE, ISI Web of Science, 
CINAHL, the Cochrane Central Registration of Controlled Trials and Research 
Registers, and Google Scholar, from inception to 12 May 2017. Grey literature was 
hand searched and bibliographies of articles checked.  
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Search strategy 
Keywords and MeSH terms relating to the following were used: TTTS, TAPS, TOPS, 
fetal death, IUGR, diseases in twins, amniotic fluid, placenta, biomarkers, 
ultrasonographic markers and prediction; and combined with “monochorionic” and 
“twins” (Appendix A). 
 
Study selection and data extraction 
Manuscripts to be included in the review were selected by two reviewers (FLM, MJH) 
independently in a two stage process; the first being review of titles and abstracts for 
selection for the second stage of full manuscript review. Where there was 
disagreement consensus was reached by a third reviewer (RKM). There was no 
restriction on language or study design. Abstracts were included if there was 
sufficient information to assess the study quality and association between the 
variable and the outcome. Data were extracted independently by FLM and MJH and 
any discrepancies resolved by RKM and MDK. Authors were contacted to clarify 
information as required. 
 
Quality assessment of included studies 
The quality of the studies was assessed by FLM and MJH using the Strengthening 
the Reporting of Observational Studies in Epidemiology (STROBE) tool (11) as this 
was considered most appropriate as the majority of studies were observational. It 
was not possible to use the recommended quality checklists for prognostic factor 
research (12) e.g. Quality in Prognosis Studies (QUIPS) (13), REMARK (14), nor 
diagnostic studies Quality Assessment of Diagnostic Accuracy Studies (QUADAS) 
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(15) due to the large number of included studies that were not focused on the 
prognostic value of factors. 
 
Assessment of heterogeneity 
Forest plots were created to visually assess outliers and any unusual results were 
investigated with sensitivity analysis. The I2 value was calculated for each meta-
analysis. A measurement ≥50% indicated a substantial risk of heterogeneity. Where 
there was significant heterogeneity (visually or statistically), a sensitivity analysis was 
performed to assess the effect.  
 
Assessment of reporting bias 
In meta-analyses with >10 studies, a funnel plot was generated using the metafunnel 
command (16) in Stata (Stata, 2015 Release 13.1 StataCorp, Texas, USA), and 
Egger’s test was performed using the metabias command (17), and with a 
significance level of 10%.  
 
Data synthesis 
Meta-analyses were reported at the per pregnancy level, not per fetus for two 
reasons. Firstly, reporting at the fetus level would require an adjustment for 
clustering, but more importantly when considering prognostic factors for pregnancy 
related diseases in multiple pregnancy, any change in management due to a 
prognostic test/model would be effected at the pregnancy level.  
 
Data synthesis for factors reported as means and medians 
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For continuous data with a normal distribution, medians were converted to means to 
enable meta-analysis. When the interquartile range (IQR) was reported, the standard 
deviation (SD) was calculated as IQR/1.35 (18). When medians were not reported 
with IQRs, the mean and SD was estimated (19). For non-normally distributed data 
(NT discordance, CRL discordance and parity) where only the median was reported, 
it was not possible to convert the median to means, therefore these results could not 
be included in meta-analysis. 
 
Data synthesis for association 
Data were extracted to create 2x2 contingency tables to compare: a) disease vs. no 
disease but where other complications may be present, and b) disease vs. normal 
pregnancy where no complications were present at all. For outcomes with more than 
three included studies, odds ratios (OR) were calculated using the metan command 
(20) in Stata, and pooled using the DerSimonian-Laird random effects model to 
account for expected clinical heterogeneity. ORs >2 were considered to demonstrate 
a moderate association (21), thus the prognostic ability of the factor was 
subsequently investigated. For continuous variables reported as, or converted into, 
means and SDs, the standardized mean difference (SMD) was calculated using the 
metan command in Stata. SMDs ≥0.5 were considered to demonstrate a moderate 
effect (22) and the prognostic ability of the factor was investigated.  
 
Data synthesis for prognostic ability 
Bivariate meta-analysis using a random effects model was performed in analyses of 
more than three studies to calculate the summary sensitivity, specificity, positive 
likelihood ratio (LR+) and negative likelihood ratio (LR-) using the metandi command 
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(23) in Stata. Hierarchical Summary Receiver Operating Characteristic (HSROC) 
curves were generated using the metandiplot command (23) to represent the level of 
uncertainty of sensitivity and specificity for bivariate analyses. Univariate analysis 
was carried out for analyses with less than four studies using MetaDiSc (v1.4116, 
Madrid, Spain)(24), with symmetrical Summary Receiver Operating Characteristic 
(SROC) curves generated. 0.5 was added to cells of 0 to perform univariate meta-
analysis, but not bivariate meta-analysis, due to the necessary use of different 
computer programs. When a prognostic factor was found to have a moderate 
association with the outcome, the predictive ability was investigated and the post-test 
probability using Fagan’s nomogram (25), which accounts for pre-test probability, 
was calculated. 
 
Results 
Study selection 
Electronic searches identified 2439 citations of which 1312 titles were excluded after 
review of titles and 743 after abstract review. The full papers of the remaining 384 
full articles were assessed (Figure 1) of which 48 studies (26-73) met the inclusion 
criteria equating to the evaluation of 5365 MC twin pregnancies. See Supplementary 
File Table 1 for the Study Characteristics of all included studies. Studies that met the 
inclusion criteria but were unable to be included in meta-analysis are described in 
Appendix B, as are individual prognostic factors that were unable to be included in 
meta-analysis. 
 
**Figure 1 about here please** 
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Study characteristics 
Supplementary File Table 1 displays the study characteristics of the included articles 
and details regarding individual measurements such as definitions of growth 
restriction. The ultrasound measurements reported were: nuchal translucency (NT), 
crown rump length (CRL), the presence of reversed a wave in the ductus venosus, 
and umbilical venous flow velocity. The maternal characteristics reported in eligible 
studies were: maternal age, ethnicity, BMI, parity and smoking. Mode of conception 
and fetal gender was also reported. The first trimester biomarkers reported were all 
from maternal serum, and included: thyroid stimulating hormone (TSH), free 
thyroxine (FT4), β-human chorionic gonadotropin (β-hCG) and pregnancy-
associated plasma protein A (PAPP-A). The most frequently investigated outcomes 
were TTTS (n=31 studies), antenatal growth restriction (n=14 studies), and postnatal 
growth restriction (n=12 studies). 
 
*Figure 2 about here please** 
 
Risk of bias of included studies 
Most studies were not designed for the recruitment of participants to examine first 
trimester potential prognostic factors. The different aspects of the ‘STROBE’ 
classification are demonstrated in Figure 2. Of note is that the studies were poor at 
stating how they addressed missing data, and which data were missing. One aspect 
of the study design that may increase the risk of heterogeneity was that different 
control groups were used: (i) MC twin pregnancies with no maternal or fetal 
complications, (ii) MC twins with no fetal complications, (iii) other MC twin 
pregnancies in the study who did not have the condition being examined but did 
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have other MC complications. For the GR outcomes, studies were classified 
according to the time that the growth measurement was performed, meaning that 5 
studies (32, 37, 41, 71, 72) despite calling their outcome IUGR, were included in the 
PGR group as their definition was based on birthweights, not antenatal ultrasound 
measurements. In calculating discordance between estimated fetal weight or 
birthweight all studies used the larger measure as the denominator. Four studies 
included in the PGR meta-analyses only measured abnormal growth by BWD, 
Moriichi et al.(56), Stagnati et al.(62), Sun et al.(64), Zhao et al.(72), meaning that 
both babies may have weighed >10th centile . All other studies that reported 
abnormal growth as an outcome had to have at least one fetus/baby <10th centile, 
except for three studies that were not able to be included in meta-analyses due to 
being the only studies which measured their potential prognostic factor (42, 45, 52). 
Not all the participants in the study by Murakami et al.(57) had delivered at the time 
the study was published, therefore only those who had delivered were included in 
our analysis. Only one funnel plot and Egger’s test was required, that did suggest 
significant publication bias in the maternal age and TTTS analysis (available on 
request from authors). 
 
Synthesis of results 
 
Meta-analysis could be performed for the following prognostic factors:  
a) Ultrasound measurements: NT >95th centile in one/both fetuses, NT discordance 
≥20%, CRL discordance ≥10%. 
b) Maternal characteristics: age, ethnicity, BMI, parity, smoking, mode of 
conception, fetal gender. 
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In total, 20 separate meta-analyses were performed; of these, 3 demonstrated a 
moderate association (OR >2), but none demonstrated a prognostic ability for any 
outcome under investigation. The results we present here are for the potential 
prognostic factors with a moderate or strong association with an outcome. All other 
results are available in Appendix C. Meta-analysis was unable to be performed on 
first trimester biomarkers because of the way the data were presented. An 
insufficient number of studies reported antenatal and postnatal growth restriction 
within the same pregnancy (27, 35), and IUFD as outcomes to include in meta-
analysis (results available from authors on request). Only 4 studies (26, 34, 55, 69) 
used a control group of ‘normal’ pregnancies, the other 44 studies used a control 
group of ‘no disease under investigation’ e.g. TTTS vs no TTTS, therefore the results 
should be considered as comparing to ‘no disease’ 
 
**Insert table 1 about here please** 
 
NT>95th centile in one/both fetuses and TTTS 
A significant association between NT>95th centile in one/both fetuses and TTTS was 
found (OR 2.29 [95%CI 1.05, 4.96] I2=6.6%, 4 studies, 615 pregnancies) (Figure 3a). 
Bivariate meta-analysis results are in table 1. The post-test probability of a positive 
result was 0.22 (95%CI 0.13, 0.35), and a negative result was 0.14 (95%CI 0.13, 
0.15), assuming pre-test probability of 0.176 based on a prevalence of 15%. See 
Figure 3b for the HSROC that shows reasonable specificity but poor sensitivity. 
 
**Figures 3a and 3b about here please** 
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CRL discordance ≥10% and TTTS 
A significant association between CRL discordance ≥10% and TTTS was found (OR 
2.43 [95%CI 1.13, 5.21] I2=14.1%, 3 studies, 708 pregnancies) (Figure 4a). 
Univariate meta-analysis results are in table 1. The post-test probability of a positive 
result was 0.28 (95%CI 0.20, 0.38), and a negative result was 0.13 (95%CI 0.12, 
0.15), assuming pre-test probability of 0.176 based on a prevalence of 15%. See 
Figure 4b for the SROC. 
 
**Figures 4a and 4b about here please** 
 
Maternal ethnicity and TTTS 
An OR >1 indicated a higher-risk of TTTS if the woman was Caucasian, and an OR 
<1 indicated a higher-risk of TTTS if the woman was non-Caucasian. A significant 
association between maternal ethnicity and TTTS was found (OR 2.12 [95%CI 1.17, 
3.83] I2=0.0%, 5 studies, 467 pregnancies) (Figure 5a). Bivariate meta-analysis 
results are in table 1. The post-test probability of a positive result was 0.17 (95%CI 
0.15, 0.19), and a negative result was 0.10 (95%CI 0.06, 0.16), assuming pre-test 
probability of 0.176 based on a prevalence of 15%. See Figure 5b for HSROC that 
shows moderate sensitivity but poor specificity. 
 
**Figures 5a and 5b about here please** 
 
Discussion 
Main findings 
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This is the first systematic review to look at first trimester potential prognostic factors 
for growth restriction in MC twins, and explore maternal characteristics and first 
trimester maternal serum biomarkers as prognostic factors for TTTS. Although a 
significant association was found between NT>95th centile in one/both fetuses and 
TTTS, and CRL discordance ≥10% and TTTS, both demonstrated poor individual 
prognostic ability. A moderate significant association between maternal ethnicity and 
TTTS was found, with Caucasian women more likely to develop TTTS, but as there 
is no plausible biological mechanism for this association thus this may reflect the 
lack of diversity within the study populations and publication bias. The other first 
trimester ultrasound measurements and maternal characteristics demonstrated no 
association with adverse outcomes. 
Only 2 studies examined first trimester maternal serum biomarkers, with Ashoor et 
al.(26) finding no significant difference in TSH, FT4 or β-hCG in those pregnancies 
that developed TTTS, and Linskens (48) noting a trend towards increased β-hCG 
and PAPP-A levels in those pregnancies that developed TTTS. As Linskens only 
reported the median and not the IQR these studies could not be combined in meta-
analysis, but this warrants further investigation due to the small study sizes and 
biological plausibility of β-hCG and PAPP-A being implicated in TTTS as markers of 
placental function. 
Strengths and limitations 
A major strength of our study was to include all possible prognostic factors and 
perform a robust statistical analysis to look at the association and prognostic ability 
of the factors. The search strategy was as inclusive as possible, and there was no 
limit on language. It was particularly important to look at modifiable factors such as 
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smoking and maternal BMI where lifestyle changes may be associated with a lower 
risk for adverse outcome. 
One limitation of our review was the different definitions that studies used for their 
control groups, variables and outcomes, which is why we did not stipulate the 
individual definitions rigidly prior to commencing the search. This was an issue for 
growth restriction as there is currently no validated standard definition of abnormal 
growth in MC twins. Consequently, the included studies defined growth restriction in 
a myriad of ways: abdominal circumference (AC) ≤5th centile, EFW <10th centile, 
EFW <5th centile, EFWD >20%, LBW <10th centile, LBW <5th centile, BWD ≥20%, 
BWD ≥25%, and in different combinations of in one twin, or both twins when not 
measuring discordance, all of which can be associated with adverse outcome. This 
issue has attempted to be investigated by a recent Delphi consensus looking at 
selective fetal growth restriction in twin pregnancy (74), and will be addressed by the 
creation of a ‘Core Outcome Set’ for ‘selective fetal growth restriction in twin 
pregnancies’(75) which is due to be completed by August 2019. In this systematic 
review, we attempted to address the problem by creating different growth restriction 
groups so as to be as inclusive as possible. The AGR group reflects real life and is 
what obstetricians base their management on. However, ultrasound scanning and 
calculation of EFWD only has a moderate ability to detect BWD with a recent 
systematic review reporting a sensitivity of 65.4% (95%CI 57.9, 72.3) and specificity 
of 90.8% (95%CI 87.1, 93.5%) for EFWD ≥20% predicting BWD ≥20%, although the 
analysis does include DC and MC twins(76). Therefore, the PGR group was included 
as an absolute measure, which avoids scan error. However, there is controversy 
whether BWD is reflective of pathological growth, and indeed what the cut-off should 
be. A recent meta-analysis, that also highlighted the problem of different definitions 
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of abnormal growth in twins, demonstrated that MC twins with BWD ≥20% (which 
also included EFWD ≥20%) had a higher risk of IUFD than concordant MC twins (OR 
2.8 [95%CI 1.3,5.8] 6 studies, 1286 pregnancies, I2 not reported) (77). Currently, MC 
twins with isolated BWD are not managed differently neonatally as this is guided by 
the actual birthweight. Additionally, BWD is not always reflective of IUGR with 21.1% 
of pregnancies with BWD ≥20% not including at least one fetus with an EFW <10th 
centile, and 21% of pregnancies with at least one fetus with an EFW <10th centile not 
demonstrating concurrent BWD(78). However, most studies in our search that 
reported growth based on postnatal measures used BWD as opposed to LBW, 
therefore it was decided to include BWD in our systematic review. The use of inter-
twin growth discordance in isolation, whether EFWD or BWD, also presents the 
problem of missing pregnancies where both twins are growth restricted, but 
irrespective of choice of definition and cut-offs, all growth outcomes have the 
common problem of not being based on specific twin growth charts, which until July 
2017 did not exist. Since performing this review, twin growth charts have been 
launched in the UK to enable more accurate assessment of twin fetal growth (79).  
Another issue was that of cut-offs for the variables as the cut-offs have not been 
appropriately validated and may not be appropriate for the study’s patient population, 
or the conditions being explored. We had planned to compare a) disease vs. no 
disease but where other complications may be present, and b) disease vs. normal 
pregnancy where no complications were present at all however as most studies used 
the former control group, we were unable to perform a separate analysis for the latter 
comparison. This has only allowed us to evaluate the ability of each potential 
prognostic factor to predict a specific condition, and not any condition (and thus we 
cannot predict the chance of the pregnancy being completely ‘normal’). 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
19 
 
 
Comparison with existing literature 
A systematic review evaluating prognostic factors up to 16 weeks for TTTS has 
recently been published, however they only looked at ultrasound prognostic markers, 
and their search was up to April 2014 (80). They stated that an increased risk of 
TTTS was associated with inter-twin NT discrepancy, NT>95th centile, and CRL 
discrepancy, but similar to our results, the prognostic ability of these factors was low. 
In addition to our inclusion of other MC twin complications, there are other 
differences between our reviews, including that Stagnati et al. did not exclude 
pregnancies with chromosomal/structural anomalies that affect first trimester 
ultrasound measurements. D’Antonio et al. performed a systematic review examining 
the ability of first trimester CRL discordance ≥10% to predict BWD ≥20%, preterm 
birth, fetal anomalies, IUFD and neonatal death, and found it also had a low 
prognostic ability for all outcomes (81). 
Conclusions and Implications 
The main clinical implication of the results of our systematic review is that they 
support the guidance from the Royal College of Obstetricians and Gynaecologists 
(RCOG) that ‘screening for TTTS by first trimester NT measurements should not be 
offered’(5). Although we have shown significant associations between first trimester 
variables and subsequent pregnancy outcome, the prognostic ability of each 
individual variable is poor, thus the results do not suggest their use to screen MC 
pregnancies in clinical practice. 
However, we have identified a gap in knowledge which has implications for research 
as most studies able to be included in the systematic review were not designed with 
the intention of assessing first trimester prognostic factors for subsequent outcomes 
in MC twins. Consequently, we designed the OMMIT study (ISRCTN13114861) a 
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large cohort study, purposefully-designed to investigate potential prognostic factors 
and explore novel prognostic markers that have not previously been evaluated: 
including alpha-fetoprotein (AFP) , pregnancy-associated plasma protein A (PAPP-
A), and s-Flt-1 (82). To avoid the problem of using non-validated cut-offs, variables 
should be kept continuous and not dichotomized.  
 
Conclusion 
We have investigated the association and prognostic ability of first trimester factors, 
including maternal characteristics, associated with TTTS, growth restriction and 
IUFD. We have found that it is not currently possible to predict adverse outcomes in 
MC twin pregnancies, and have revealed a lack of research investigating first 
trimester biomarkers in MC twin pregnancies. Different assessment methods and 
definitions of each variable and outcome were an issue and this highlights the need 
for a large cohort study to evaluate these factors. 
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Tables 
Table 1 Summary of accuracy of prognostic factors with a significant association with 
twin-twin transfusion syndrome 
Prognostic 
factor 
Sensitivity 
(95%CI) 
Specificity 
(95%CI) 
Positive 
likelihood ratio 
(95%CI) 
Negative 
likelihood ratio 
(95%CI) 
NT>95th centile 
in one/both 
fetuses* 
0.118 
(0.035, 0.330) 
0.926 
(0.882, 0.954) 
1.589 
(0.589, 4.290) 
0.953 
(0.830, 1.094) 
CRL 
discordance 
≥10%† 
0.203  
(0.120, 0.308) 
0.908  
(0.882, 0.929) 
2.180  
(1.147, 4.142) 
0.904  
(0.794, 1.030) 
Maternal 
ethnicity* 
0.826 
(0.672, 0.917) 
0.278  
(0.135, 0.917) 
1.145  
(0.941, 1.394) 
0.624 
(0.349, 1.117) 
*Analysed by bivariate analysis. †Analysed by univariate analysis. CRL: crown-rump 
length, NT: nuchal translucency 
 
Figure legend 
Figure 1 Flow diagram of study inclusion 
Figure 2 Quality assessment of included studies according to ‘Strengthening The 
Reporting of Observational studies in Epidemiology’ (STROBE) checklist 
Figure 3a Forest plot of association between NT>95th centile (NT>95th) in one/both 
fetuses and twin-twin transfusion syndrome (TTTS) 
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Figure 3b Hierarchical summary receiver operating characteristic curves (HSROC) 
for NT>95th centile in one/both fetuses and twin-twin transfusion syndrome (TTTS) 
studies. This visually represents the global summary of prognostic factor 
performance by plotting the mean sensitivity against the reversed mean specificity 
produced by the bivariate analysis. The ellipses represent the 95% confidence 
intervals of the mean sensitivities and specificities and 95% prediction region. The 
closer the values are to the top left corner, the greater the accuracy of the prognostic 
factor. 
Figure 4a Forest plot of association between crown-rump length discordance ≥10% 
(CRLD>10%) and twin-twin transfusion syndrome (TTTS) 
Figure 4b Summary receiver operating characteristic curves for crown-rump length 
discordance ≥10% and twin-twin transfusion syndrome 
Figure 5a Forest plot of association between maternal ethnicity and twin-twin 
transfusion syndrome (TTTS) 
Figure 5b Hierarchical summary receiver operating characteristic curves for maternal 
ethnicity and twin-twin transfusion syndrome studies. This visually represents the 
global summary of prognostic factor performance by plotting the mean sensitivity 
against the reversed mean specificity produced by the bivariate analysis. The 
ellipses represent the 95% confidence intervals of the mean sensitivities and 
specificities and 95% prediction region. The closer the values are to the top left 
corner, the greater the accuracy of the prognostic factor. 
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Table 1 Summary of accuracy of prognostic factors with a significant association with 
twin-twin transfusion syndrome 
Prognostic 
factor 
Sensitivity 
(95%CI) 
Specificity 
(95%CI) 
Positive 
likelihood ratio 
(95%CI) 
Negative 
likelihood ratio 
(95%CI) 
NT>95th centile 
in one/both 
fetuses* 
0.118 
(0.035, 0.330) 
0.926 
(0.882, 0.954) 
1.589 
(0.589, 4.290) 
0.953 
(0.830, 1.094) 
CRL 
discordance 
≥10%† 
0.203  
(0.120, 0.308) 
0.908  
(0.882, 0.929) 
2.180  
(1.147, 4.142) 
0.904  
(0.794, 1.030) 
Maternal 
ethnicity* 
0.826 
(0.672, 0.917) 
0.278  
(0.135, 0.917) 
1.145  
(0.941, 1.394) 
0.624 
(0.349, 1.117) 
*Analysed by bivariate analysis. †Analysed by univariate analysis. CRL: crown-rump 
length, NT: nuchal translucency 
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Citations excluded by title 
(n=1312) or abstract (n=743) 
Studies excluded based on full article 
n=336 
No first trimester factors n=144 
Included fetal anomalies n=21 
Review article n=4 
Not divided by chorionicity n=13 
Comparing chorionicity, not outcome n=56 
Case reports<5 n=3 
Overlapping data with another paper n=15 
Unobtainable n=6 
No control group n=30 
No adverse outcome group n=42 
Inter-twin discordance <20% n=2 
Studies included in 
systematic review n=48 
Citations retrieved for detailed 
evaluation of full article n=384 
Potentially relevant citations 
identified by search strategy 
(Inception-May 2017) 
n=2439 
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Supplementary file Table 1 Characteristics of studies eligible for inclusion 
 
Abbreviation: 1st T: 1st trimester, AC: abdominal circumference, AFI: amniotic fluid index, ART: assisted reproduction technology, AUC: area under (receiver operating 
characteristic) curve, β-hCG: beta-human chorionic gonadotropin, BMI: body mass index, BWD: birthweight discordance, C-section: Caesarean section, CRL: crown-rump 
length, DA: diamniotic, DC: dichorionic, DV: ductus venosus (Doppler), EFWD: estimated fetal weight discordance, FLA: fetoscopic laser ablation, GD: growth discordance, 
IUFD: intrauterine fetal demise, IUGR: intrauterine growth restriction, IVF: in vitro fertilisation, LBW: low birthweight, MA: monoamniotic, MC: monochorionic, MoM: multiple of 
median, NT: nuchal translucency, PAPP-A: pregnancy-associated plasma protein A, proBNP: prohormone of brain natriuretic peptide, sIUGR: selective intrauterine growth 
restriction, TAPS: twin anaemia-polycythaemia sequence, TOP: termination of pregnancy, TRAP: twin reversed arterial perfusion syndrome, TTTS: twin-twin transfusion 
syndrome, UAD: umbilical artery Doppler, USS: ultrasound scans, UVVF: umbilical venous volume flow A 
*additional information/clarification obtained by contacting the authors 
Author  
year 
Study design, 
data 
collection, 
enrolment 
Study population 
(Location, years, inclusion 
and exclusion criteria) 
Total 
pregna
ncies 
eligible 
for 
study 
Total MC 
pregnanci
es 
analysed 
in study 
Outco
mes 
used in 
review 
Outcome 
definition used 
by study 
Control group(s) 
definitions used 
by study 
Potential 
prognostic factors 
Ashoor 
2013(26) 
Case series, 
prospective, 
not stated 
Location: ?1 centre in UK  
Years: 2006-2011 
INC: twin pregnancies with live 
fetuses at 11-13 weeks 2 
livebirths at ≥33 weeks, or 
severe TTTS necessitating 
FLA 
EXC: Maternal history of 
hypo/hyperparathyroidism or 
diabetes, fetal abnormalities, 
pre-eclampsia, BW<5th centile 
Not 
stated 
77 TTTS ‘polyhydramnios 
surrounding the 
recipient fetus 
whose bladder 
was enlarged, 
oligo-
/anhydramnios 
around the 
smaller donor 
fetus whose 
bladder was 
collapsed.’ 
Normal 
pregnancies with 
2 livebirths at >33 
weeks 
Thyroid hormones, 
mode of conception 
(spontaneous or 
use of ovulation 
inducing drugs), 
maternal age 
(median), BMI 
(median), ethnicity 
Bajoria 
2006(27) 
Unclear, not 
stated, not 
stated 
Location: 1 centre in UK  
Years: not stated 
INC: MC pregnancies 
with/without discordant growth 
EXC: chronic TTTS, 
single/double IUFD, 
intrapartum stillbirth, 
aneuploidy, structural 
abnormalities, pregnancies 
Not 
stated 
32 BWD 
and 
sIUGR 
in same 
pregna
ncy 
BWD ≥20% with 
no 
polyhydramnios in 
the larger twin, 
and smaller twin 
must have AC ≤5th 
centile with 
abnormal UAD, in 
same pregnancy 
BWD ≤10% and 
normal amniotic 
fluid volume in 
both twins 
Maternal age 
(median), ethnicity 
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with: diabetes, hypertension, 
renal disease, cardiac disease 
Bajoria 
2007(28) 
Unclear, not 
stated, not 
stated 
Location: ? centres in UK  
Years: not stated 
INC: MC pregnancies 
with/without TTTS 
EXC: single/double IUFD, 
intrapartum stillbirth, 
aneuploidy, structural 
abnormalities, pregnancies 
with: diabetes, hypertension, 
renal disease, cardiac disease 
Not 
stated 
30 TTTS AFI ≥40cm in 
larger twin and 
≤4cm in smaller 
twin. The smaller 
twin must also 
have IUGR, and 
the EFWD ≥15%, 
all in same 
pregnancy. 
Concordant 
growth and AFI 
≤24cm 
Maternal age 
(median) 
Baraa Allaf 
2014(29) 
Cohort, 
retrospective 
search of 
database with 
prospectively 
recorded data, 
consecutive 
enrolment to 
database and 
study 
Location: 9 centres in USA  
Years: 2007-2011 
INC: 2 live fetuses at 11-13+6 
weeks 
EXC: chromosomal 
abnormalities, major 
congenital malformations, 
single/double IUFD in 1st T 
 
Not 
stated 
177 TTTS Polyhydramnios 
(DVP ≥8cm before 
20 weeks, or 
≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in the 
donor twin 
No TTTS NT >95th centile in 
one/both fetuses, 
NT discordance 
≥20% (AUC), CRL 
discordance (AUC), 
combined NT and 
CRL discordance 
(AUC) 
IUGR EFW<10th centile 
in either fetus 
No IUGR NT >95th centile in 
one/both fetuses 
Ben-Ami 
2016(30) 
Cohort, not 
stated, not 
stated 
Location: 7 centres in Israel, 
Spain, Germany and Canada 
Years: 1997-2013 
INC: MCDA twin pregnancies 
undergoing NT scan at 11-14 
weeks with 2 live fetuses 
EXC: fetal congenital/structural 
abnormalities, single/double 
IUFD, higher order multiple 
reductions, non-IVF fertility 
treatments 
337 327 TTTS Polyhydramnios 
(DVP ≥8cm before 
20 weeks, or 
≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in the 
donor twin 
No TTTS Mode of conception 
(spontaneous or 
IVF/ICSI), maternal 
age (mean) 
Carver 
2011(31) 
Cohort, 
retrospective 
collection of 
prospectively 
recorded data, 
consecutive 
Location: 1 centre in USA  
Years: 2000-2009 
INC: MCDA twins delivered at 
hospital and who underwent 
antenatal care at that hospital 
EXC: No sonographic 
examinations in 2nd T, no 
available antenatal records 
151 145 TTTS Polyhydramnios 
(DVP ≥8cm before 
20 weeks, or 
≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in the 
No TTTS Maternal age 
(mean), ethnicity 
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donor twin 
Chai 
2013(32) 
Cohort, 
retrospective, 
not stated 
Location: 1 centre in China 
Years: 2005-2012 
INC: MCDA pregnancies 
EXC: Aneuploidy/fetal 
anomalies, TTTS, TRAP, 
TAPS, LBW in both twins 
Not 
stated 
113 LBW BW <10th centile 
in at least 1 twin 
No LBW Maternal age 
(mean) 
Chang 
2009(33) 
Cohort, 
prospective, 
not stated 
Location: 1 centre in Taiwan  
Years: 2006-2008 
INC: live-born MCDA twins 
with a placenta able to be 
studied postnatally  
EXC: fetal anomalies, single 
IUFD, TTTS 
53 51 sIUGR  EFW <10th 
percentile in 1 
twin, with and 
without UAD 
abnormalities 
No TTTS or 
sIUGR 
Maternal age 
(mean) 
Chang 
2016(34) 
Cohort, 
unclear,  
consecutive 
Location: 1 centre in Taiwan 
Years: 2013-2015 
INC: MC twins delivered by C-
section with cord blood 
samples 
EXC: women who went into 
labour, TTTS, TAPS, 
congenital/structural or genetic 
malformations 
 
Not 
stated 
32 sIUGR  This is not clear. 
The terms sIUGR, 
fetal weight and 
BWD are used 
inter-changeably. 
Authors state: 
BWD >20% and 
BW <10th centile 
in 1 twin 
according to 
pregnancy birth 
weight chart, 
which is 
subdivided to 
those with and 
without UAD 
abnormalities 
“Normal” MC 
twins, definition 
not stated 
Fetal gender 
Chang 
2017(35) 
 
Cohort, 
unclear, 
unclear 
Location: 1 centre in Taiwan 
Years: 2013-2014 
INC: MC twins delivered at 
centre with cord blood 
samples 
EXC: TTTS, 
congenital/structural or genetic 
malformations 
Not 
stated 
24 BWD 
and 
sIUGR 
in same 
pregna
ncy 
EFW <10th centile 
and BWD >20% in 
same pregnancy 
No sIUGR Maternal age 
(mean), parity 
(mean) 
Cosmi 
2013(36) 
Unclear, 
prospective, 
selected but 
unclear how 
Location: 1 centre in Italy 
Years: 2009-2011 
INC: MCDA pregnancies 
selected from previously 
Not 
stated 
12 sIUGR EFW<10th centile 
in smaller twin, 
>10th centile 
larger twin, with 
EFW >10th centile 
in both twins and 
confirmed after 
birth, and normal 
Maternal age 
(median), parity 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
published cohort but inclusion 
criteria not stated 
EXC: unknown last menstrual 
period, unknown chorionicity, 
triplets, TTTS or related 
conditions, MCMA, 1st T 
discrepancy in CRL>5 days, 
structural/chromosomal 
abnormalities, single IUFD, 
selective feticide, maternal 
history of cardiovascular 
disease, endocrine disorders, 
clinical chorioamnionitis, 
maternal consumption of: 
alcohol, drugs of abuse, 
nicotine 
and without UAD 
abnormalities 
UAD 
El Kateb 
2007(37) 
Cohort, 
prospective, 
consecutive 
Location: 1 centre in France 
Years: 2002-2006 
INC: MCDA pregnancies with 
1st T NT and CRL 
measurements 
EXC: chromosomal 
abnormalities or congenital 
malformations 
Not 
stated  
103 TTTS Polyhydramnios 
(DVP ≥8cm before 
20 weeks, or 
≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in the 
donor twin 
No TTTS NT >95th centile 
(per fetus), CRL 
discordance ≥10% 
(per pregnancy) 
LBW BW <5th percentile 
(per twin analysis) 
No LBW NT >95th centile 
(per fetus), CRL 
discordance ≥10% 
(per fetus)  
Flöck 
2013(38) 
Cohort, 
retrospective 
search of 
database with 
prospectively 
recorded data, 
enrolment to 
database and 
study not 
stated 
Location: ? centre in Germany  
Years: 2004-2010 
INC: ‘unaffected’ twins on 
perinatal database 
EXC: structural fetal 
malformations, aneuploidy, 
vanishing twin, embryo 
reduction 
849 
fetuses 
(does 
not 
state 
how 
many 
pregna
ncies) 
706 
fetuses, 
equating to 
353 
pregnancie
s in total, 
73/353 
MCDA, 
280 DCDA 
sIUGR Not stated No sIUGR Mode of conception 
(spontaneous or 
IVF/ICSI) 
Fratelli 
2011(39) 
Cohort, 
retrospective, 
retrospective 
search of 
Location: 1 centre in Italy 
Years: 2001-2009 
INC: 1st T viable MC twin at 
11-13+6 weeks and follow-up 
136 135 TTTS Polyhydramnios 
(DVP ≥8cm before 
20 weeks, or 
≥10cm after 20 
No TTTS NT discordance 
≥20%, NT >95th 
centile in one, NT 
>95th centile in both, 
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database with 
prospectively 
recorded data, 
consecutive 
enrolment to 
database but 
unclear to 
study 
at that centre 
EXC: pregnancies referred at 
later gestation, aneuploidy 
 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in the 
donor twin 
NT >95th centile in 
one/both fetuses, 
NT discordance 
(median), NT 
discordance (AUC), 
CRL discordance 
≥10%, CRL 
discordance 
(median), CRL 
discordance (AUC) 
sIUGR EFW<10th 
percentile and 
abnormal UAD in 
same pregnancy 
No sIUGR NT discordance 
≥20%, NT >95th 
centile in one, NT 
>95th centile in both, 
NT >95th centile in 
one/both fetuses, 
NT discordance 
(median), NT 
discordance (AUC), 
CRL discordance 
≥10%, CRL 
discordance 
(median), CRL 
discordance (AUC) 
IUFD Miscarriage <24 
weeks or 
spontaneous 
death of at least 1 
fetus 
No IUFD NT discordance 
≥20%, NT >95th 
centile in one, NT 
>95th centile in both, 
NT >95th centile in 
one/both fetuses, 
NT discordance 
(median), CRL 
discordance ≥10%, 
CRL discordance 
(median) 
Fujioka 
2014(40) 
Cohort, 
prospective, 
not stated 
Location: 1 centre in Japan  
Years: 2007-2010 
INC: MCDA twins with N-
terminal proBNP levels 
measured at delivery 
EXC: congenital/chromosomal 
abnormalities, TTTS, referred 
to centre >26 weeks 
124 73 sIUGR EFW <10th 
percentile at 18-
26 weeks 
No sIUGR Mode of conception 
(spontaneous or 
ART), fetal gender, 
maternal age 
(median) 
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Ghalili 
2013(41) 
Cohort, 
retrospective 
search of 
database with 
prospectively 
recorded data, 
consecutive 
enrolment to 
database and 
study 
Location: 2 centres in Australia 
Years: 2006-2010 
INC: MCDA twins undergoing 
1st T scan,  
EXC: higher order multiples, 
pregnancies not conceived by 
IVF or spontaneously, non-
viable or lethal structural 
anomalies at 12 week scan, 
unable to determine mode of 
conception or pregnancy 
outcome 
312 294 LBW in 
one/ 
both 
twins 
BW <10th centile 
in one/both twins 
BW >10th centile 
in both twins 
Mode of conception 
(spontaneous or 
IVF) 
    
    
TTTS Polyhydramnios 
(DVP ≥8cm before 
20 weeks, or 
≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in the 
donor twin 
No TTTS Mode of conception 
(spontaneous or 
IVF) 
Johansen 
2014(42) 
Cohort, 
retrospective 
search of 
database with 
prospectively 
recorded data, 
enrolment to 
database and 
study unclear 
Location: 14 centres in 
Denmark 
Years: 2004-2006 
INC: 2 live DA fetuses and 
chorionicity determined in 1st T 
EXC: unknown chorionicity, 
MCMA, reduction from higher 
order multiple, selective 
feticide or termination due to 
severe malformation/ 
chromosomal anomaly 
 
281 260 BWD BWD ≥20% BWD <20% CRL discordance 
≥10%, CRL 
discordance ≥4% 
(OR), CRL 
discordance ≥5.5% 
(OR), CRL 
discordance ≥7% 
(OR), CRL 
discordance ≥10% 
(OR) 
Fetal 
loss of 
at least 
1 fetus 
Miscarriage ≤23+6 
weeks, IUFD 
>23+6 weeks 
2 livebirths CRL discordance 
≥10%, CRL 
discordance ≥10% 
(AUC), CRL 
discordance ≥4% 
(OR), CRL 
discordance ≥5.5% 
(OR), CRL 
discordance ≥7% 
(OR), CRL 
discordance ≥10% 
(OR) 
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Kagan 
2007(43) 
Cohort, 
retrospective 
search of 
database with 
prospectively 
recorded data, 
enrolment to 
database and 
study unclear 
Location: 1 centre in UK 
Years: 2001-2006 
INC: MCDA pregnancies 
undergoing combined 1st T 
aneuploidy screening 
EXC: chromosomal or 
structural defects, pregnancies 
with missing outcome data 
 
560 470 TTTS 
 
Severe TTTS 
requiring FLA. 
TTTS defined as: 
polyhydramnios 
(DVP ≥8cm before 
20 weeks, or 
≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in the 
donor twin 
No TTTS NT discordance 
≥20%, NT 
discordance 
(median), NT 
discordance (AUC), 
CRL discordance 
≥10%, CRL 
discordance 
(median), CRL and 
NT discordance 
(AUC) 
IUFD 
(‘early’) 
Single/double 
IUFD at 13-18 
weeks with no 
intervention 
Not clear NT discordance 
(AUC), CRL and NT 
discordance (AUC) 
Kusanovic 
2008(44) 
Case-control, 
database with 
prospectively 
recorded data, 
enrolment to 
database and 
study unclear 
Location: ? centres in USA 
and China  
Years: not stated 
INC: MCDA twin pregnancies 
16-26 weeks 
EXC: pre-eclampsia at time of 
venepuncture, fetal congenital 
anomalies 
Not 
stated 
69 TTTS Polyhydramnios 
(DVP ≥8cm) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in the 
donor twin 
No TTTS Maternal age 
(median), gravida, 
height (median), 
weight (median), 
BMI (median), 
smoking 
Lewi 
2008a(45) 
Cohort, 
prospective, 
not stated 
Location: 2 centres in Belgium 
and Germany 
Years: 2004-2007 
INC: MCDA twin pregnancies 
EXC: TTTS, spontaneous 
miscarriage, IUFD <16 weeks, 
structural anomalies that 
influence biometry 
 
208 163 GD 
(‘late’ 
onset) 
BWD ≥25% but 
EFWD<20% at 20 
weeks 
BWD <25% CRL difference 
(mean) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Lewi 
2008b(46) 
Cohort, 
prospective, 
not stated 
Location: 2 centre in Belgium 
and Germany  
Years: 2002-2007 
INC: MCDA twin pregnancies 
with 2 live fetuses at 11-14 
weeks 
EXC: single/double IUFD, 
TRAP, structural anomalies 
202 200 TTTS polyhydramnios 
(DVP ≥8cm before 
20 weeks, or 
≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in the 
donor twin 
No TTTS CRL discordance 
≥6mm 
Linskens 
2009(47) 
Cohort, 
retrospective 
search of 
database with 
prospectively 
recorded data, 
consecutive 
enrolment to 
database and 
study 
Location: 1 centre in 
Netherlands  
Years: 2004-2008 
INC: MCDA twins undergoing 
combined 1st T aneuploidy 
screening and followed up 
EXC: single/ double IUFD, 
preterm birth 
 
 
 
61 55 TTTS polyhydramnios 
(DVP ≥8cm before 
20 weeks, or 
≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in the 
donor twin 
No TTTS and birth 
>26 weeks 
NT discordance 
≥20%, NT 
discordance 
≥3.5mm, NT 
discordance 
(median), NT 
discordance (AUC), 
CRL discordance 
(median), maternal 
age (median), 
ethnicity, smoking, 
parity, mode of 
conception 
(spontaneous or 
ART) 
Linskens 
2010(48) 
Cohort, 
retrospective 
search of 
database with 
prospectively 
recorded data, 
consecutive 
enrolment to 
database and 
study 
Location: 1 centre in 
Netherlands  
Years: 2004-2009 
INC: MCDA twins undergoing 
combined 1st T aneuploidy 
screening and followed up 
EXC: not stated 
 
56 51 TTTS polyhydramnios 
(DVP ≥8cm before 
20 weeks, or 
≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in the 
donor twin 
No TTTS or single 
or double IUFD 
PAPP-A (median 
MoM), β-hCG 
(median MoM) 
Maiz 
2009(49) 
Cohort, 
prospective, 
unclear 
enrolment 
Location: 1 centre in UK 
Years: 2006-2008 
INC: MCDA and DCDA twin 
pregnancies with 2 live fetuses 
at 11-13+6 weeks 
EXC: unable to measure DV in 
both fetuses, outcome data 
missing 
733 
MCDA 
and 
DCDA 
(does 
not 
state 
number 
179 
(MCDA but 
we exclude 
4 from 
analysis 
with 
aneuploidy
/major 
Severe 
TTTS 
Severe TTTS 
requiring FLA or in 
which the 
fetus(es) died 
prior to FLA: 
‘ultrasound 
diagnosis of 
hydramnios in one 
No TTTS or 
aneuploidy/major 
fetal defects 
DV abnormal in 
one, DV abnormal 
in both, DV 
abnormal in 
one/both fetuses 
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 of 
MCDA) 
defects, 
therefore 
175) 
twin and 
anhydramnios in 
the other, and 
absent or 
reversed end 
diastolic flow in 
either the 
umbilical artery or 
ductus venosus in 
one or both 
fetuses’ 
sIUGR Severe sIUGR 
requiring FLA, 
definition of 
sIUGR not stated 
No sIUGR or 
aneuploidy/major 
fetal defects 
DV abnormal in 
one, DV abnormal 
in both, DV 
abnormal in 
one/both fetuses 
Single 
IUFD or 
miscarri
age 
Gestation at IUFD 
not stated but 
must be >14 
weeks 
No single IUFD or 
aneuploidy/major 
fetal defects 
DV abnormal in 
one, DV abnormal 
in both, DV 
abnormal in 
one/both fetuses 
Matias 
2005(50) 
Cohort, 
prospective, 
not stated 
Location: 1 centre in Portugal 
Years: not stated 
INC: MCDA pregnancies 
referred to unit for ‘routine 1st T 
ultrasonographic assessment’ 
EXC: not stated 
 
Not 
stated 
50 TTTS Anhydramnios 
and nonvisible 
bladder in the 
donor in 
combination with 
polyhydramnios 
and dilated 
bladder in the 
recipient. 
No TTTS, 2 
livebirths 
Raw NT values, NT 
discordance ≥20%, 
DV abnormal in 
one, DV abnormal 
in both, DV 
abnormal in 
one/both fetuses, 
maternal age 
(median) 
Matias 
2010(51) 
Cohort, 
prospective, 
not stated 
Location: 1 centre in Portugal 
Years: 1997-2008 
INC: MCDA pregnancies 
undergoing 1st T assessment 
EXC: malformations (e.g. 
megacystis), single IUFD 
 
 
 
 
 
 
 
Not 
stated 
99 TTTS Oligohydramnios 
and non-visible 
bladder in the 
donor in 
combination with 
polyhydramnios 
and dilated 
bladder in the 
recipient  
No TTTS NT per fetus 
(mean), NT 
difference (mean), 
NT ratio (mean), NT 
difference (AUC), 
NT ratio (AUC), 
CRL per fetus 
(mean), CRL 
difference (mean), 
CRL ratio (mean), 
CRL difference 
(AUC), CRL ratio 
(mean), DV 
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abnormal in one, 
DV abnormal in 
both, DV abnormal 
in one/both fetuses, 
DV abnormal (AUC) 
Matias 
2011(52) 
Cohort, 
prospective, 
not stated 
Location: 2 centres in Portugal 
and UK 
Years: 2006-2009 (UK), 1998-
2009 (Portugal) 
INC: MC pregnancies that did 
not require antenatal 
interventions, and resulted in 2 
healthy livebirths 
EXC: major fetal 
abnormalities, single/double 
IUFD, FLA for TTTS or sIUGR 
326 237 BWD BWD ≥20% BWD <20% DV abnormal in 
one/both fetuses 
*McDonald 
2017(53) 
Case series, 
prospective, 
consecutive 
Location:1 centre in Australia 
Years: 2011-2014 
INC: All MCDA twins attending 
for antenatal care at centre  
EXC: patients referred to 
centre for FLA, but remainder 
of care elsewhere 
162 156 TTTS Polyhydramnios 
(DVP ≥8cm before 
20 weeks, or 
≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in the 
donor twin 
No TTTS or 
chromosomal/ 
structural 
anomalies (parity, 
ethnicity). 
No TTTS, sIUGR, 
IUFD, TAPS, 
chromosomal/stru
ctural anomalies 
(maternal age, 
BMI) 
Maternal age 
(mean), BMI 
(mean), ethnicity, 
parity 
sIUGR EFW ≤10th centile 
in one or both 
twins, and/or 
EFWD >20% 
No sIUGR or 
chromosomal/ 
structural 
anomalies (parity, 
ethnicity). 
No TTTS, sIUGR, 
IUFD, TAPS, 
chromosomal/stru
ctural anomalies 
(maternal age, 
BMI) 
Maternal age 
(mean), BMI 
(mean), ethnicity, 
parity 
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Single 
or 
double 
IUFD 
Gestation at IUFD 
not stated, but 
median 22.0 (IQR 
20.1-30.0 weeks) 
thus presumed 2nd 
trimester 
No IUFD or 
chromosomal/ 
structural 
anomalies 
Maternal age 
(mean), BMI 
(mean), ethnicity, 
parity 
Memmo 
2012(55) 
Cohort, 
retrospective 
search of 
database with 
prospectively 
recorded data, 
consecutive 
enrolment to 
database and 
study 
Location: 1 centre in UK  
Years: 2000-2010 
INC: MC pregnancies with 1st 
T CRL and NT measurements 
EXC: TTTS Stage 1 managed 
conservatively who did not 
undergo FLA, MCMA, 
aneuploidy, fetal structural 
anomalies, spontaneous 
pregnancy loss <16 weeks 
 
279 242 TTTS Polyhydramnios 
(DVP ≥8cm before 
20 weeks, or 
≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in the 
donor twin 
2 healthy 
livebirths at >34 
weeks with no 
TTTS or sIUGR 
for all outcomes 
except parity 
which was 
compared to no 
TTTS. 
NT discordance 
(median), NT larger 
twin (median), NT 
smaller twin 
(median), CRL 
discordance 
(median), CRL 
larger twin 
(median), CRL 
smaller twin 
(median), CRL 
discordance (AUC), 
maternal age 
(median), parity 
sIUGR 
‘early’ 
1 twin EFW <10th 
centile, before 26 
weeks gestation 
and no signs of 
TTTS 
2 healthy 
livebirths at >34 
weeks with no 
TTTS or sIUGR 
except parity 
which was 
compared to no 
sIUGR. 
NT discordance 
(median), NT larger 
twin (median), NT 
smaller twin 
(median), CRL 
discordance 
(median), CRL 
larger twin 
(median), CRL 
smaller twin 
(median), CRL 
discordance (AUC), 
maternal age 
(median), parity 
*Miura  
2014(54) 
Cohort, not 
stated, not 
stated 
Location: 1 centre in Japan 
Years: not stated 
INC: MC pregnancies who 
visited centre at 12-21 weeks 
EXC: not stated 
Not 
stated 
28 TTTS Polyhydramnios 
(DVP ≥8cm) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in the 
donor twin 
No TTTS or 
chromosomal/ 
structural 
anomalies 
Maternal age 
(mean), parity 
Moriichi 
2013(56) 
Cohort, 
prospective, 
not stated 
Location: 1 centre in Japan 
Years: 2007-2011 
INC: MC pregnancies with 2 
Not 
stated 
36 BWD BWD ≥20% BWD <20% Maternal age 
(mean), parity 
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livebirths 
EXC: chromosomal 
aberrations, congenital 
anomalies, IUFD, TTTS 
Murakami 
2011(57) 
Cohort, 
retrospective 
search of 
database with 
prospectively 
recorded data, 
consecutive 
enrolment to 
database and 
study 
Location: 1 centre in Japan 
Years: 2006-2010 
INC: Twins pregnancies 
attending for antenatal care at 
centre 
EXC: congenital anomalies 
associated with IUGR, 
multifetal pregnancy reduction 
 
125 (51 
MCDA, 
74 
DCDA) 
42 TTTS Polyhydramnios 
(DVP ≥8cm) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in the 
donor twin 
No TTTS Mode of conception 
(spontaneous or 
IVF/ovulation 
induction) 
IUFD Single/double 
IUFD >16 weeks 
No IUFD Mode of conception 
(spontaneous or 
IVF/ovulation 
induction) 
*Sarais  
2015(58) 
 
Cohort, 
retrospective 
search of 
database with 
prospectively 
recorded data, 
enrolment to 
database and 
study unclear 
Location: 1 centre in Italy 
Years: 2007-2011 
INC: MC pregnancies 
undergoing antenatal care at 
centre, which progressed >16 
weeks 
EXC: higher order multiples, 
those presenting >16 weeks 
Not 
stated 
145 TTTS Not stated No TTTS or 
chromosomal/ 
structural 
anomalies 
Mode of conception 
(spontaneous or 
IVF) 
IUFD Single and double 
IUFD, >16 weeks  
No IUFD or 
chromosomal/ 
structural 
anomalies 
Mode of conception 
(spontaneous or 
IVF) 
Schrey 
2013(59) 
Cohort, not 
stated, not 
stated 
Location: ? centres in Canada  
Years: not stated 
INC: ‘potential discordant MC 
twin pregnancies as 
candidates for placental 
sampling were identified in the 
antenatal period’ 
EXC: fetal abnormalities, 
syndromes or infections, pre-
eclampsia, diabetes, placental 
tumours 
Not 
stated 
15 BWD BWD ≥20% BWD <20% 
(all smaller twins 
also below the 
10th centile) 
Fetal gender 
Sebire 
2000(60) 
Cohort, 
retrospective 
search of 
database with 
prospectively 
recorded data, 
consecutive 
enrolment to 
database 
Location: ? centre in UK 
Years: unclear start date but 
delivered prior to June 1999 
INC: MCDA pregnancies with 
2 live fetuses at 10-14 weeks 
gestation, with outcome 
information available 
EXC: structural/chromosomal 
anomalies, TOP 
303 287 Severe 
TTTS 
Anhydramnios 
and no-visible 
bladder in the 
donor fetus in 
combination with 
polyhydramnios 
and a dilated 
bladder in the 
recipient fetus, 
No TTTS NT >95th centile per 
fetus, NT >95th 
centile in one/both 
fetuses 
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unclear, but 
consecutive to 
study 
 which resulted in 
either miscarriage 
or fetal death or 
required 
intrauterine 
treatment or post-
mortem evidence 
that the cause of 
death was TTTS. 
Sooranna 
2001(61) 
Unclear, 
prospective, 
not stated 
Location: ? centres in UK 
Years: not stated 
INC: MC and DCDA 
pregnancies 
EXC: chronic TTTS, single 
IUFD, structural/chromosomal 
abnormalities, selective 
feticide, embryo reduction, 
maternal complications: 
hypertension, pre-eclampsia, 
renal/cardiac disease 
Not 
stated 
29 sIUGR EFWD ≥20% with 
smaller twin’s AC 
≤5th centile and 
abnormal UAD in 
same pregnancy, 
with absence of 
polyhydramnios in 
the larger twin’s 
sac 
EFWD ≤10% and 
normal AFI 
throughout 
pregnancy 
Fetal gender 
Stagnati 
2016(62) 
Cohort, 
retrospective 
search of 
database with 
prospectively 
recorded data, 
consecutive 
enrolment to 
database and 
study 
Location: 1 centre in Italy  
Years: 2008-2013 
INC: MCDA pregnancies of 
with 1st T scan and antenatal 
care at centre 
EXC: referral after 1st T and/or 
incomplete follow-up, fetal 
structural abnormalities or 
abnormal karyotype, TTTS, 
TAPS, sIUGR or EFWD ≥25% 
at <28 weeks 
 
172 136 sIUGR EFW <5th centile No sIUGR Maternal age 
(median), BMI 
(median), mode of 
conception 
(spontaneous or 
ART), parity 
BWD BWD >25% BWD ≤25% Maternal age 
(median), BMI 
(median), mode of 
conception 
(spontaneous or 
ART), parity 
Sueters 
2006(63) 
Cohort, 
prospective, 
consecutive 
Location: 1 centre in 
Netherlands  
Years: 2002-2004 
INC: MCDA pregnancies, <16 
weeks at referral, no signs of 
TTTS at initial USS 
EXC: fetal abnormalities 
25 23 TTTS Polyhydramnios 
(DVP ≥8cm before 
20 weeks, or 
≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in the 
donor twin 
No TTTS NT >95th centile in 
one/both fetuses, 
maternal age 
(median), parity 
(median) 
Sun  
2017(64) 
Case-control, 
retrospective, 
Location: 1 centre in China 
Years: not stated 
Not 
stated 
14 BWD BWD >20% BWD <10% and 
normal UAD 
Maternal age 
(mean), fetal gender 
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 not stated INC: MCDA twins 
EXC: pre-eclampsia, TTTS, 
TAPS, fetal 
structural/chromosomal 
anomalies, maternal or 
pregnancy complications 
Tai  
2007(65) 
Cohort, 
prospective, 
not stated 
Location: 1 centre in USA 
Years: 2000-2006 
INC: twin pregnancies 
undergoing 1st T aneuploidy 
screening with 2 fetal 
heartbeats detected 
EXC: chromosomal/major 
congenital anomalies, 1st/2nd 
T TOP, MCMA 
Not 
stated 
43 TTTS Not stated No TTTS CRL discordance 
≥11% 
Taylor-
Clarke 
2013(66) 
Case-control, 
prospective, 
consecutive 
Location: 1 centre in UK 
Years: not stated 
INC: MCDA pregnancies 
referred for ultrasound 
assessment from local 
maternity units  
EXC: not stated 
 
Not 
stated 
55 TTTS Polyhydramnios 
(DVP ≥8cm before 
20 weeks, or 
≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in the 
donor twin 
No TTTS Maternal age 
(median) 
Torres-
Torres 
2010(67) 
Cohort, 
retrospective, 
consecutive 
Location: 1 centre in Mexico 
Years: 2008-2009 
INC: MCDA twins undergoing 
antenatal care at centre 
EXC: not stated 
 
Not 
stated 
34 (but we 
excluded 4 
from 
analysis 
with 
aneuploidy
/major 
defects, 
therefore 
30) 
TTTS Polyhydramnios 
(DVP ≥8cm) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in the 
donor twin 
‘Normal’ with no 
complications, 
structural 
abnormalities, 
TTTS or sIUGR 
Maternal age 
(median) 
sIUGR EFW >10th centile 
in one fetus 
‘Normal’ with no 
complications, 
structural 
abnormalities, 
TTTS or sIUGR 
Maternal age 
(median) 
*Velayo 
2012(68) 
Case-control, 
retrospective, 
not stated  
Location: ? centre in ? country 
Years: 2008-2009 
INC: MCDA twins 
EXC: not stated 
 
Not 
stated 
35 TTTS Polyhydramnios in 
1 twin, 
oligohydramnios 
in the other twin. 
FLA performed for 
all TTTS patients 
No TTTS or 
chromosomal/ 
structural 
anomalies. EFWD 
<15%, no 
polyhydramnios or 
oligohydramnios, 
UAD, MCA and 
Maternal age 
(mean), BMI 
(mean), ethnicity, 
parity, mode of 
conception 
(spontaneous or not 
stated) 
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DV Dopplers 
normal. 
Yinon 
2014(69) 
Cohort, 
prospective, 
not stated 
Location: 1 centre in Israel 
Years: 2010-2012 
INC: MCDA twins 
EXC: chronic hypertension, 
pre-gestational diabetes, 
congenital/chromosomal 
abnormalities, single IUFD at 
presentation 
 
 
60 45 TTTS Polyhydramnios 
(DVP ≥8cm before 
20 weeks, or 
≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in the 
donor twin 
Normal: 
appropriately 
grown, EFWD 
<25%, normal 
amniotic fluid 
volumes, normal 
UADs, similar 
MCA-PSV in both 
twins for all 
outcomes, except 
smoking which is 
no TTTS. 
Maternal age 
(median), gravida, 
BMI (median), 
smoking 
37 sIUGR EFW <10th centile 
in one fetus and 
EFWD ≥25% in 
same pregnancy 
Normal: 
appropriately 
grown, EFWD 
<25%, normal 
amniotic fluid 
volumes, normal 
UADs, similar 
MCA-PSV in both 
twins for all 
outcomes, except 
smoking which is 
no sIUGR 
Maternal age 
(median), gravida, 
BMI (median), 
smoking 
Zanardini 
2014(70) 
Cohort, 
prospective, 
not stated 
Location: 1 centre in Italy  
Years: 2009-2012 
INC: MCDA pregnancy 
attending centre for antenatal 
care 
EXC: MCMA, congenital 
cardiac anomaly/arrhythmia, 
fetal anomaly, TRAP, IUFD at 
presentation, maternal age 
<18 years, higher order 
multiples, patients lost to 
follow-up, TTTS diagnosed at 
<17 weeks 
139 100 TTTS Polyhydramnios 
(DVP ≥8cm before 
20 weeks, or 
≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in the 
donor twin 
‘Uncomplicated’ 
throughout 
pregnancy, plus 4 
with sIUGR (not 
defined) 
Mode of conception 
(spontaneous or not 
stated), maternal 
age (median), parity 
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Zhang 
2015(71) 
Not stated, 
retrospective, 
not stated 
Location: ? centres in China 
Years: 2009-2013 
INC: MCDA twins 
EXC: severe maternal 
complications, TTTS, IUFD 
Not 
stated 
24 LBW BW <10th centile 
in one twin 
No LBW Maternal age 
(mean), BMI 
(mean), fetal gender 
*Zhao 
2013(72) 
Cohort, 
retrospective, 
consecutive 
Location: 1 centre in The 
Netherlands 
Years: 2002-2012 
INC: MCDA twins with stored 
placentas 
EXC: TRAP, IUFD, higher 
order multiples, if underwent 
FLA or selective feticide  
 
Not 
stated 
235 TTTS Polyhydramnios 
(DVP ≥8cm) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in the 
donor twin 
No TTTS or 
chromosomal/ 
structural 
anomalies  
Fetal gender 
 
   BWD BWD ≥25% No BWD or 
chromosomal/ 
structural 
anomalies 
Fetal gender 
TAPS Antenatally MCA-
PSV 
>1.5 MoM in the 
donor and MCA-
PSV <1.0 MoM in 
the recipient, 
and/or 
postnatally inter-
twin haemoglobin 
difference >8.0 
g/dl, and at 
least one of the 
following: 
reticulocyte count 
ratio >1.7 and 
placenta with only 
small (diameter < 
1mm) vascular 
anastomoses 
No TAPS or 
chromosomal/ 
structural 
anomalies 
Fetal gender 
Zoppi 
2014(73) 
Cohort, 
prospective, 
not stated 
Location: ? centre in Italy  
Years: 2010-2012 
INC: MCDA pregnancies 11-
14 weeks gestation 
EXC: malformations, single or 
double IUFD <16 weeks, TOP 
<16 weeks 
 
87 71 TTTS Diagnosed <26 
weeks. 
Polyhydramnios 
(DVP ≥8cm) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in the 
donor twin 
No TTTS, sIUGR, 
amniotic fluid 
discordance 
UVVF larger twin 
(median), UVVF 
smaller twin 
(median), NT larger 
twin (median), NT 
smaller twin 
(median), CRL 
larger twin (median) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
CRL smaller twin 
(median) 
70 sIUGR AC <5th centile in 
one fetus, and 
EFWD >25% in 
same pregnancy 
?No TTTS, 
sIUGR, amniotic 
fluid discordance 
UVVF larger twin 
(median), UVVF 
smaller twin 
(median), NT larger 
twin (median), NT 
smaller twin 
(median), CRL 
larger twin (median) 
CRL smaller twin 
(median) 
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Appendix A Search strategy 
1. fetofetal blood transfusion or fetofetal transfusion or twin twin transfusion 
syndrome or twin to twin transfusion syndrome or twin-twin transfusion syndrome 
or twin-to-twin transfusion.mp. 
2. twin anemia* polycythemia* sequence or TAPS.mp. 
3. twin oligohydramnios-polyhydramnios sequence or TOPS.mp. 
4. fetal death or intrauterine death or intrauterine demise or single twin demise or 
perinatal mortality or perinatal outcome* or neonatal mortality.mp. 
5. small-for-gestational age or lbw or small for gestational age or sgr or small for 
date* or small for gestation* or fgr or iugr or intrauterine growth retard* or 
intrauterine growth restrict* or fetal growth retard* or fetal growth restrict* or 
growth restrict* or growth retard* or “Fetal growth retardation” or “Infant, Low 
Birth Weight” or low birth weight.mp. 
6. Diseases in Twins/ 
7. amniotic fluid or amniotic fluid metabolism.mp. 
8. placenta* or placental circulation or placental metabolism or placental blood 
supply or amnion or chorion.mp. 
9. alpha-fetoprotein* or angiogenesis inducing agents or biological markers or 
chorionic gonadotropin, beta subunit or angiogenesis inducing agents or 
metabolomics* or vascular endothelial growth factor* or placental growth 
factor.mp. 
10. neck/ultrasonography or nuchal translucency.mp. crown-rump length.mp. or 
biometry.mp or blood flow velocity.mp. or regional blood flow.mp. or umbilical 
arteries*.mp. or umbilical veins*.mp. or Doppler.mp. or ductus venosus.mp. 
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11. predictive value or tests* or risk assessment or risk factors* or prognostic* 
factors* or predictive* factors* or prognostic model or prognosis* or prediction* or 
predictor or formula or algorithm.mp. 
12. twins*.mp. 
13. monochorionic*.mp. 
14. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 
15. 12 and 13 and 14  
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Appendix B Studies and potential prognostic factors not included in meta-
analyses 
 
Studies 
In calculating discordance between ultrasound measures, all studies used the larger 
measure as the denominator, apart from Memmo et al.(55) who used the smaller NT 
as the denominator, however as they only reported the median NT discordance, 
there were too few studies to include this variable in meta-analysis. Chang et al.(33) 
could not be included in the analysis at all because they divided their AGR group into 
those with and without umbilical artery Doppler abnormalities and as the variable of 
maternal age was reported as a mean, the groups could not be combined. Cosmi et 
al.(36) was also not included in the maternal age analysis for the same reason as 
Chang et al., and Sun et al.(64) divided their control group into two sub-groups and 
thus could not be included in the maternal age analysis for the same reason. Velayo 
et al.(68) could not be included in this analysis because they did not report the 
standard deviations. 
Flöck et al.(38) was not included in the TTTS outcome as the participants were also 
included in the larger cohort reported by Ben-Ami et al.(30). Zhao et al.(72) was not 
included in the TTTS analysis because they excluded those with TTTS who had 
undergone FLA and the group would have been heterogeneous. El Kateb et al.(37) 
could not be included in the PGR group because the variables and outcomes were 
only reported per fetus. The ‘early onset’ growth discordance group in the study by 
Lewi et al.(45) was not included as their definition of the outcome and variable both 
included difference in CRL. Kagan et al.(43) could not be included in the IUFD 
outcome because they only reported sufficient information for a 2x2 contingency 
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table on their sub-group of IUFD at 13-18 weeks. Nine studies were unable to be 
included in any meta-analysis due to an insufficient number of studies reporting the 
same variable and outcome(42, 45, 46, 48, 49, 51, 52, 65, 83) (results available from 
authors on request). 
Potential prognostic factors 
The following first trimester ultrasound measurements, maternal characteristics and 
serum biomarkers were reported for the outcomes under examination, but were 
unable to be included in meta-analysis (results available from authors on request). 
Ultrasound measurements 
The following factors were reported by less than 3 studies thus could not be included 
in meta-analysis: abnormal ductus venosus Doppler in one/both fetuses(49, 51); 
umbilical venous volume flow in fetus 1 ≥ fetus 2(73). NT discordance ≥10%, ≥30%, 
≥40%, ≥50%(43); NT discordance >3.5 mm(47); NT difference(38, 51); NT ratio(51); 
NT larger twin(55, 73); NT smaller twin(55, 73); NT any twin(51). CRL discordance 
>4%, ≥5%, 5.5%, 7%, 10%, ≥15%, ≥20%(39, 42, 43); CRL discordance >11%(65); 
CRL discordance ≥6 mm, ≥12 mm(46); CRL difference(51); CRL ratio(51); CRL 
larger twin(55, 73); CRL smaller twin(55, 73); CRL any twin(51).  
Maternal characteristics 
Gravida (44, 69), height, and weight (44). 
First trimester serum markers 
Four first trimester maternal serum markers were investigated: β-hCG, PAPP-A, TSH 
and FT4, but meta-analysis was not possible. Linskens et al.(48) reported a trend in 
difference in β-hCG MoM in pregnancies with TTTS, and uncomplicated MC twins 
(median 1.99 vs 1.53 respectively, p=0.32, 51 pregnancies) and PAPP-A (median 
1.94 vs 1.69 respectively, p=0.51, 51 pregnancies). Ashoor et al.(26) reported no 
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difference in TSH, FT4 or free β-hCG MoM in 17 pregnancies with TTTS and ‘normal 
outcome twins’, although the authors do not state if the control group included DC 
twins thus the number of MC twin pregnancies in the analysis is not clear. The 
following levels are reported in the TTTS and ‘normal outcome twins’ respectively: 
TSH (median 1.38 [IQR 0.52–2.05] vs 1.00 [IQR 0.26–1.36] respectively, p=0.424, 
number of pregnancies not clear),  FT4 MoM (median 0.94 [IQR 0.90–1.16] vs 0.98 
[IQR 0.91–1.08], p=0.773, number of pregnancies not clear), free β-hCG MoM 
(median 0.95 [IQR 0.51–2.22] vs 1.00 [IQR 0.69–1.36], p=0.997, number of 
pregnancies not clear). These serum markers were only reported in the context of 
TTTS, and not the other outcomes. 
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Appendix C Meta-analyses with no moderate/strong prognostic association 
NT discordance ≥20% and TTTS 
There was a trend towards a significant association between NT discordance ≥20% 
and TTTS, however there was a high-risk of heterogeneity (OR 2.48 [95%CI 0.90, 
6.84] I2=67.6%, 4 studies, 710 pregnancies) (Figure C.1). To investigate the 
heterogeneity a sensitivity analysis was performed removing Kagan et al.(43) as it 
only included those with severe TTTS requiring FLA in their group, whereas others 
included those with a diagnosis of TTTS irrespective of intervention. Removing 
Kagan et al. made no difference to the results or level of heterogeneity (results not 
shown) therefore this study was included. On visual inspection of the forest plot, 
Matias et al. was noted to be an outlier, however there was no reason to remove the 
study based on study design or characteristics, therefore this study was included. 
Figure C.1 Forest plot of association between NT discordance ≥20% and TTTS 
 
Maternal age and TTTS 
No significant association between maternal age and TTTS was found (SMD 0.02 
[95%CI -0.19, 0.24] I2=54.9%, 15 studies, 1336 pregnancies) (Figure C.2). Although 
the I2 suggests a high-risk of heterogeneity, there were no obvious outliers from 
visual inspection of the forest plot or in study design. The funnel plot (Figure C.3) 
NOTE: Weights are from random effects analysis
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does appear asymmetrical, although Egger’s test does not suggest small-study 
effects with p=0.576.  
Figure C.2 Forest plot of association between maternal age and TTTS 
 
Figure C.3 Funnel plot of maternal age and TTTS studies 
NOTE: Weights are from random effects analysis
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Maternal age and AGR 
No significant association between maternal age and AGR was found (SMD -0.02 
[95%CI -0.62, 0.57] I2=87.5%, 6 studies, 529 pregnancies) (Figure C.4). To 
investigate the high-risk of heterogeneity, a sensitivity analysis was performed 
removing Memmo et al.(55), Fujioka et al.(40) and Stagnati et al.(62) as these 
studies restricted their definitions of AGR based on gestation. Removing these 
studies made no difference to the results or level of heterogeneity (results not 
shown) therefore the studies were included. An additional sensitivity analysis was 
performed by removing Yinon et al.(69) and McDonald et al.(53) following visual 
assessment of the forest plot. This decreased the I2 to 0.0% and produced a 
significant association between maternal age and AGR (SMD 0.32 [05%CI 0.08, 
0.56], 4 studies, 359 pregnancies) (forest plot not shown) although the effect of 
maternal age is small thus the prognostic ability was not further investigated. When 
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the studies were examined in more detail, these were the only 2 studies in the meta-
analysis that included twins with estimated fetal weight discordance (EFWD) in their 
abnormal growth group, whereas the definition used in the other 4 studies required 
the EFW of 1 twin to be <10th centile(40, 55, 67) or 5th centile(62).     
Figure C.4 Forest plot of association between maternal age and antenatal 
growth restriction (AGR) 
 
Maternal age and PGR 
No significant association between maternal age and PGR was found (SMD 0.05 
[95%CI -0.75, 0.85] I2=78.3%, 3 studies, 173 pregnancies) (Figure C.5). It was not 
possible to investigate the high-risk of heterogeneity as there were too few studies.  
Figure C.5 Forest plot of association between maternal age and postnatal 
growth restriction (PGR) 
 
Maternal age and AoPGR 
NOTE: Weights are from random effects analysis
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No significant association between maternal age and AoPGR was found (SMD -0.07 
[95%CI -0.51, 0.37] I2=82.1%, 10 studies, 622 pregnancies) (Figure C.6). To 
investigate the high-risk of heterogeneity, a sensitivity analysis was performed 
removing Memmo et al.(55) and Fujioka et al.(40) as these studies restricted their 
definitions of AGR based on gestation. However, removing these studies made no 
difference to the results or level of heterogeneity (results not shown) therefore these 
studies were included. 
Figure C.6 Forest plot of association between maternal age and antenatal or 
postnatal growth restriction (AoPGR) 
 
Maternal BMI and TTTS 
No significant association between maternal BMI and TTTS was found (SMD -0.03 
[95%CI -0.30, 0.25] I2=0.0%, 4 studies, 291 pregnancies) (Figure C.7). 
Figure C.7 Forest plot of association between maternal BMI and TTTS 
NOTE: Weights are from random effects analysis
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Maternal BMI and AGR 
No significant association between maternal BMI and AGR was found (SMD 0.40 
[95%CI -0.37, 1.16] I2=87.9%, 3 studies, 281 pregnancies) (Figure C.8). Following 
visual assessment of the forest plot, Stagnati(62) was noted to be an outlier, which 
was the only study in the meta-analysis that did not include EFWD in their definition 
of abnormal growth. It was not possible to investigate this further as there were too 
few studies. 
Figure C.8 Forest plot of association between maternal BMI and antenatal 
growth restriction (AGR) 
 
Maternal BMI and AoPGR 
No significant association between maternal BMI and AoPGR was found (SMD 0.03 
[95%CI -0.49, 0.55] I2=55.4%, 3 studies, 194 pregnancies) (Figure C.9). It was not 
possible to investigate the high-risk of heterogeneity as there were too few studies. 
NOTE: Weights are from random effects analysis
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Figure C.9 Forest plot of association between maternal BMI and antenatal or 
postnatal growth restriction (AoPGR) 
 
Parity and TTTS 
An OR >1 indicated a higher-risk of TTTS if the woman was nulliparous, and an OR 
<1 indicated a higher-risk of TTTS if the woman was multiparous. No significant 
association between parity and TTTS was found (OR 1.08 [95%CI 0.58, 2.02] 
I2=46.4%, 6 studies, 615 pregnancies) (Figure C.10). 
Figure C.10 Forest plot of association between parity and TTTS 
 
Parity and AGR  
An OR >1 indicated a higher-risk of AGR if the woman was nulliparous, and an OR 
<1 indicated a higher-risk of AGR if the woman was multiparous. There appears to 
be an association between parity and AGR (OR 1.73 [95%CI 1.11, 2.70] I2=6.8%, 4 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 55.4%, p = 0.106)
Zhang
Author
McDonald
Yinon
2015
Year
2017
2014
9
(n)
47
15
AoPGR
26
mean
25
24.25
AoPGR
2.00
SD
4.90
3.61
AoPGR
15
(n)
86
22
Control
27.40
mean
25.00
22.70
Control
2.60
SD
5.40
2.00
Control
0.03 (-0.49, 0.55)
-0.58 (-1.43, 0.26)
SMD (95% CI)
0.00 (-0.36, 0.36)
0.56 (-0.11, 1.23)
100.00
23.18
Weight
46.80
30.02
%
  0-2 -1 1
NOTE: Weights are from random effects analysis
Overall  (I-squared = 46.6%, p = 0.096)
Velayo
Author
Linskens
Zanardini
Memmo
Miura
McDonald
2012
Year
2009
2014
2012
2014
2017
Nulliparous,
9
TTTS
7
4
47
6
10
Nulliparous,
6
NoTTTS
20
35
77
13
73
Multiparous,
5
TTTS
7
8
55
5
4
Multiparous,
15
NoTTTS
21
53
63
4
68
1.08 (0.58, 2.02)
4.50 (1.06, 19.11)
OR (95% CI)
1.05 (0.31, 3.53)
0.76 (0.21, 2.71)
0.70 (0.42, 1.17)
0.37 (0.07, 1.89)
2.33 (0.70, 7.78)
100.00
%
12.60
Weight
15.71
14.83
30.37
10.65
15.83
  1.1 .5 2 5 10 25
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
studies, 545 pregnancies) (Figure C.11) although as it was a weak association with 
an OR <2 this was not further investigated. 
Figure C.11 Forest plot of association between parity and antenatal growth 
restriction (AGR) 
 
Parity and AoPGR 
An OR >1 indicated a higher-risk of AoPGR if the woman was nulliparous, and an 
OR <1 indicated a higher-risk of AoPGR if the woman was multiparous. A trend 
towards an association between parity and AoPGR was found (OR 1.56 [95%CI 
0.97, 2.50], I2=0.0%, 4 studies, 445 pregnancies) (Figure C.12). 
Figure C.12 Forest plot of association between parity and antenatal or 
postnatal growth restriction (AoPGR) 
 
Maternal smoking and TTTS 
NOTE: Weights are from random effects analysis
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An OR >1 indicated a higher-risk of TTTS if the woman was a smoker, and an OR <1 
indicated a higher-risk of TTTS if the woman was a non-smoker. No significant 
association between maternal smoking and TTTS was found (OR 1.64 [95%CI 0.50, 
5.40] I2=0.0%, 3 studies, 184 pregnancies) (Figure C.13). 
Figure C.13 Forest plot of association between maternal smoking and TTTS 
 
Mode of conception and TTTS 
An OR >1 indicated a higher-risk of TTTS if the pregnancy was conceived by ART, 
and an OR <1 indicated a higher-risk of TTTS if the pregnancy was conceived 
spontaneously. No significant association between mode of conception and TTTS 
was found (OR 1.06 [95%CI 0.57, 1.99] I2=22.0%, 7 studies, 1040 pregnancies) 
(Figure C.14). 
Figure C.14 Forest plot of association between mode of conception and TTTS 
NOTE: Weights are from random effects analysis
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Mode of conception and AGR 
An OR >1 indicated a higher-risk of AGR if the pregnancy was conceived by ART, 
and an OR <1 indicated a higher-risk of AGR if the pregnancy was conceived 
spontaneously. No significant association between mode of conception and AGR 
was found (OR 1.79 [95%CI 0.68, 4.70] I2=0.0%, 3 studies, 282 pregnancies) (Figure 
C.15).  
Figure C.15 Forest plot of association between mode of conception and 
antenatal growth restriction (AGR) 
 
Mode of conception and AoPGR 
An OR >1 indicated a higher-risk of AoPGR if the pregnancy was conceived by ART, 
and an OR <1 indicated a higher-risk of AoPGR if the pregnancy was conceived 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 22.0%, p = 0.261)
Ghalili
Sarais
Ben-Ami
Murakami
Ashoor
Author
Linskens
Zanardini
2013
2015
2016
2011
2013
Year
2009
2014
12
1
1
4
10
ART,
TTTS
2
0
64
9
42
6
28
ART,
NoTTTS
2
4
36
24
36
5
9
Spont,
TTTS
12
12
182
111
248
27
30
Spont,
NoTTTS
39
84
1.06 (0.57, 1.99)
0.95 (0.46, 1.93)
0.51 (0.06, 4.25)
0.16 (0.02, 1.23)
3.60 (0.74, 17.56)
1.19 (0.42, 3.36)
OR (95% CI)
3.25 (0.41, 25.60)
0.75 (0.04, 14.81)
100.00
35.62
7.73
8.41
12.60
23.46
%
Weight
8.05
4.12
  1.1 .5 2 5 10 25
NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.926)
Author
Fujioka
Flöck
Stagnati
Year
2014
2013
2016
AGR
4
1
2
ART,
NoAGR
8
8
4
ART,
AGR
12
6
28
Spont,
NoAGR
49
58
102
Spont,
1.79 (0.68, 4.70)
OR (95% CI)
2.04 (0.53, 7.92)
1.21 (0.13, 11.38)
1.82 (0.32, 10.46)
100.00
Weight
50.82
18.59
30.59
%
  1.1 .5 2 5 10 15
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
spontaneously. As Ghalili et al.(41) presented both birthweight discordance and low 
birth weight in one baby, and in two babies, the latter two measures were combined 
to reflect low birthweight in at least one twin. No association between mode of 
conception and AoPGR was found (OR 1.02 [95%CI 0.64, 1.65], I2=0.0%, 3 studies, 
440 pregnancies) (Figure C.16). 
Figure C.16 Forest plot of association between mode of conception and 
antenatal or postnatal growth restriction (AoPGR) 
 
Fetal gender and PGR 
An OR >1 indicated a higher-risk of PGR if the fetuses were male, and an OR <1 
indicated a higher-risk of PGR if the fetuses were female. No significant association 
between fetal gender and PGR was found (OR 0.73 [95%CI 0.42, 1.29] I2=0.0%, 4 
studies, 288 pregnancies) (Figure C.17). Investigation of unusual results with 
sensitivity analysis revealed no significant difference.  
Figure C.17 Forest plot of association between fetal gender and postnatal 
growth restriction (PGR) 
NOTE: Weights are from random effects analysis
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Fetal gender and AoPGR 
An OR >1 indicated a higher-risk of AoPGR if the fetuses were male, and an OR <1 
indicated a higher-risk of AoPGR if the fetuses were female. No significant 
association between fetal gender and AoPGR was found (OR 0.68 [95%CI 0.43, 
1.08], I2=0.0%, 7 studies, 422 pregnancies) (Figure C.18).  
Figure C.18 Forest plot of association between fetal gender and antenatal or 
postnatal growth restriction (AoPGR)
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Appendix D MOOSE Checklist 
 
 
 Reported on page Brief Description 
Reporting of background should include 
Problem definition 4-5 Monochorionic twins are considered 
high-risk pregnancies. No prognostic 
test is currently available to predict 
which monochorionic twin pregnancies 
will develop twin-twin transfusion 
syndrome, intrauterine growth 
restriction, intrauterine fetal death, 
therefore these pregnancies are closely 
monitored antenatally which has an 
impact on patients, health care 
providers and resources. 
Hypothesis/research question statement 5 To assess the ability of first trimester 
pregnancy related factors (ultrasound 
measurements, maternal 
characteristics, biomarkers) to predict 
complications in MC twin pregnancies.  
Description of study outcomes 6-7 Twin-twin transfusion syndrome, 
antenatal growth restriction, postnatal 
growth restriction, single intrauterine 
fetal death, double intrauterine fetal 
death 
Type of exposure or intervention used 6 First trimester ultrasound 
measurements, biomarkers and 
maternal characteristics 
Type of study designs used 8 No limitation, but must be able to assess 
association between variable and 
outcome 
Study population 5 Women with a monochorionic diamniotic 
twin pregnancy. Pregnancies affected 
by chromosomal/structural anomalies, 
monoamniotic twins, double fetal loss 
prior to 14 weeks gestation, or twin 
reversed arterial perfusion were 
excluded.  
Reporting of search strategy should include 
Qualifications of searchers (eg librarians 
and investigators) 
9 FLM MBChB, MRes 
MJH undergraduate medical student 
learning how to perform a systematic 
review and meta-analysis 
RKM MBChB, PhD, MRCOG 
MDK MBBS, DSc, MD, FRCOG 
Search strategy, including time period 
used in the synthesis and key words 
8 
Appendix A 
Keywords and MeSH terms relating to 
the following were used: TTTS, TAPS, 
TOPS, fetal death, IUGR, diseases in 
twins, amniotic fluid, placenta, 
biomarkers, ultrasonographic markers 
and prediction; and combined with 
“monochorionic” and “twins”. The date of 
publication was limited from inception to 
12 May 2017. 
Effort to include all available studies, 
including contact with authors 
8 
Acknowledgements 
Effort was made to contact authors 
where appropriate 
Databases and registries searched 7 Cochrane Library databases. 
Search software used, name and 7 Medline, Web of Science, Embase, 
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version, including special features used 
(eg explosion) 
CINAHL, Google Scholar 
Use of hand searching (eg reference lists 
of obtained articles) 
7 Grey literature and reference lists were 
hand searched 
List of citations located and those 
excluded, including justification 
Figure 1 See Figure 1 
Method of addressing articles published 
in languages other than English 
8 There was no limitation on language 
and articles were translated by health 
care professionals with an adequate 
level of understanding. 
Method of handling abstracts and 
unpublished studies 
8 Abstracts were included if there was 
sufficient information to assess the 
study quality and association between 
the variable and the outcome 
Description of any contact with authors 8 Effort was made to contact authors 
where appropriate although no replies 
were received. 
Reporting of methods should include 
Description of relevance or 
appropriateness of studies assembled 
for assessing the hypothesis to be tested 
5,6, 8 Detailed inclusion and exclusion criteria 
are described in main text. 
Rationale for the selection and coding of 
data (eg sound clinical principles or 
convenience) 
8 A data extraction sheet was developed 
(available on request) and information 
extraction is described in main text. 
Assessment of confounding (eg 
comparability of cases and controls in 
studies where appropriate) 
12 Different control groups were used, 
which are outlined in the text. 
Assessment of study quality, including 
blinding of quality assessors, 
stratification or regression on possible 
predictors of study results 
8, Figure 2 STROBE was used as described in text. 
Assessment of heterogeneity 9 Heterogeneity was explored by 
assessing the distribution of results in 
the Forest plots and I-squared. 
Description of statistical methods (eg 
complete description of fixed or random 
effects models, justification of whether 
the chosen models account for 
predictors of study results, dose-
response models, or cumulative meta-
analysis) in sufficient detail to be 
replicated 
9-11 See text for details 
Provision of appropriate tables and 
graphics 
Figures 1-5, 
Appendix C 
Supplementary File 
Table 1 
See text for details 
Reporting of results should include 
Graphic summarizing individual study 
estimates and overall estimate 
Figures 3-5, 
Appendix C 
Forest plots were provided for all meta-
analyses. 
Table giving descriptive information for 
each study included 
Supplementary File 
Table 1 
Detailed in Table 1 
Results of sensitivity testing (eg 
subgroup analysis) 
14-15 
Table 2 
Detailed in text and table 2.  
Indication of statistical uncertainty of 14-15 Detailed in text. 95% CI reported and I2 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
findings where appropriate. 
Reporting of discussion should include 
Quantitative assessment of bias (eg 
publication bias) 
12-13 Detailed in text 
Justification for exclusion (eg exclusion 
of non-English language citations) 
5 The exclusion criteria were based on 
affecting the potential prognostic factors 
Assessment of quality of included 
studies 
12-13 
Figure 2 
STROBE was used, the results are 
detailed in text and Figure 2 
Reporting of conclusions should include 
Consideration of alternative explanations 
for observed results 
16-19 Detailed in text 
Generalization of the conclusions (eg 
appropriate for the data presented and 
within the domain of the literature review) 
16-19 Detailed in text 
Guidelines for future research 19-20  Detailed in text 
Disclosure of funding source 1 FLM is funded by the Richard and Jack 
Wiseman Trust (Registered charity 
number: 1036690). 
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson, D, Rennie D, Moher D, Becker, BJ, Sipe TA, 
Thacker SB for the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Group.  Meta-
analysis of Observational Studies in Epidemiology. A Proposal for Reporting  JAMA. 
2000;283(15):2008-2012. 
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PRISMA 2009 Checklist 
Section/topic  # Checklist item  Reported 
on page # 
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
5 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
5 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
5-6 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
7 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
Appendix 
A 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
8 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
8 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
6-8 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
8-9 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  9-11 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis.  
9-11 
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PRISMA 2009 Checklist 
Page 1 of 2  
Section/topic  # Checklist item  Reported on page # 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
9 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
7, 8 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
11 
Figure 1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) 
and provide the citations.  
Supplementary 
File Table 1 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  12-13 
Figure 2 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
13-15 
Appendix B 
Appendix C 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  13-15 
Appendix B 
Appendix C 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  Figure 3b, 4b, 
5b 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 
16]).  
13-15 
Appendix B 
Appendix C 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
15 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval 
of identified research, reporting bias).  
16-17 
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PRISMA 2009 Checklist 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future 
research.  
19-20 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders 
for the systematic review.  
1 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. 
doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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